Ribavirin
證據等級: L3 | 預測適應症: 10 個
## 藥師評估報告
Ribavirin：從 C 型肝炎到慢性 B 型肝炎病毒感染
一句話總結
Ribavirin 是一種抗病毒藥物，原本與干擾素或其他抗病毒藥物併用治療慢性 C 型肝炎。TxGNN 模型預測它可能對**慢性 B 型肝炎病毒感染 (Chronic Hepatitis B Virus Infection)** 有效，目前有 **30+ 個臨床試驗**支持這個研究方向。
快速總覽
| 項目 | 內容 |
|---|---|
| 原適應症 | 慢性 C 型肝炎（與 peginterferon 或 DAA 併用） |
| 預測新適應症 | chronic hepatitis B virus infection、hepatopulmonary syndrome、early-onset familial noncirrhotic portal hypertension、idiopathic copper-associated cirrhosis、hepatoportal sclerosis、primitive portal vein thrombosis、chronic hepatitis C virus infection、hepatic porphyria、IgG4-related pachymeningitis、IgG4-related mesenteritis |
| TxGNN 預測分數 | 99.86% |
| 證據等級 | L3 |
| 台灣上市 | 已上市 |
| 許可證數 | 多張 |
| 建議決策 | Proceed with Guardrails |
預測適應症詳細分析
1. chronic hepatitis B virus infection L1 99.86% 主要分析
為什麼這個預測合理？
Ribavirin 是一種核苷類似物，具有廣譜抗病毒活性。它的作用機轉包括：
- 抑制病毒 RNA 聚合酶
- 誘導病毒基因組突變
- 調節宿主免疫反應
雖然 ribavirin 主要被批准用於 C 型肝炎的治療，但其廣譜抗病毒活性使其對其他病毒（包括 B 型肝炎病毒）可能具有潛在療效。在某些情況下，特別是 B/C 型肝炎合併感染或 D 型肝炎（需要 B 型肝炎病毒作為輔助病毒）的患者中，ribavirin 與干擾素的組合已被研究。
然而，需要注意的是，目前 B 型肝炎的標準治療是核苷類似物（如 entecavir、tenofovir）或干擾素，ribavirin 並不是標準方案的一部分。
臨床試驗
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT02332720 | PHASE2 | COMPLETED | 413 | A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safe... |
| NCT00720434 | PHASE2 | COMPLETED | 35 | A Phase 2, Randomized, Placebo Controlled, Dose Ranging Study To Evaluate Pegint... |
| NCT03226717 | N/A | UNKNOWN | 100 | Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy |
| NCT01957319 | PHASE3 | COMPLETED | 72 | Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ri... |
| NCT01623336 | PHASE2, PHASE3 | UNKNOWN | 740 | Safety and Efficacy of BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys... |
| NCT00412334 | PHASE4 | COMPLETED | 104 | Antiviral Effect of 4 Regimens of PEGASYS Plus Copegus in Patients With Genotype... |
| NCT00048724 | PHASE3 | COMPLETED | 631 | PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjec... |
| NCT01278134 | PHASE2 | COMPLETED | 170 | INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment With a... |
| NCT02243293 | PHASE2, PHASE3 | COMPLETED | 694 | A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, an... |
| NCT01318694 | PHASE3 | COMPLETED | 1081 | A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety ... |
| NCT00703118 | PHASE3 | COMPLETED | 663 | A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of 2 Regimens of... |
| NCT02247440 | PHASE4 | COMPLETED | 18 | Response to Peg-interferon and Ribavirin for the Treatment of HCV Infection in H... |
| NCT00356486 | PHASE4 | COMPLETED | 74 | Open, Multicentre and Randomised Phase IV Study to Evaluate Viral Kinetics in th... |
| NCT01336010 | PHASE4 | COMPLETED | 82 | Treatment of Recently Acquired Hepatitis C Virus Infection |
| NCT01731301 | PHASE4 | UNKNOWN | 20 | A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving H... |
| NCT01425203 | PHASE3 | COMPLETED | 238 | Safety and Efficacy of Boceprevir in Combination With Peginterferon Alfa-2b Plus... |
| NCT01055821 | PHASE2 | COMPLETED | 140 | A Phase II Randomized, Multicenter, Open-label Study of TG4040 (MVA-HCV) in Comb... |
| NCT00117533 | PHASE4 | UNKNOWN | 20 | A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2... |
| NCT01852604 | PHASE2 | COMPLETED | 143 | A Randomized Study to Evaluate the Safety and Efficacy of IDX719 in Combinations... |
| NCT02648022 | NA | COMPLETED | 83 | Integrated Care for Patients With High Risk Substance Use and Psychiatric Disord... |
| NCT01464827 | PHASE2 | COMPLETED | 580 | A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, ... |
| NCT01628094 | PHASE2 | COMPLETED | 110 | Randomized, Open-Label, Multicenter Study of Safety, Efficacy, and Tolerability ... |
| NCT02023099 | PHASE3 | COMPLETED | 363 | A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy an... |
| NCT02243280 | PHASE2 | COMPLETED | 174 | An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacok... |
| NCT00593151 | PHASE1, PHASE2 | COMPLETED | 32 | An Open-Label, 3-Panel, Dose-Escalation Study to Assess the Safety and Tolerabil... |
| NCT00088504 | PHASE2 | COMPLETED | 315 | A Phase 2b Study of Merimepodib in Combination With Pegylated Interferon Alfa-2a... |
| NCT00911963 | PHASE1, PHASE2 | COMPLETED | 49 | A Phase l b/II a, Multicenter, Randomized, Double-Blinded, and Placebo-Controlle... |
| NCT00807001 | PHASE1, PHASE2 | COMPLETED | 41 | A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Ant... |
| NCT01463592 | PHASE3 | UNKNOWN | 90 | An Open Labelled, Active Controlled, Three Arm, Parallel- Group Study of the Saf... |
| NCT01057667 | PHASE2 | COMPLETED | 168 | A Randomized, Double-blinded, Multicenter Study to Evaluate the Antiviral Effica... |
| NCT01717326 | PHASE2 | COMPLETED | 573 | A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Com... |
| NCT00100659 | PHASE3 | COMPLETED | 114 | Pegylated Interferon +/- Ribavirin for Children With Hepatitis C |
| NCT01197157 | PHASE2, PHASE3 | COMPLETED | 200 | Impact of Nitazoxanide on Virologic Responses in Chronic HCV Infected Patients W... |
| NCT00188240 | NA | UNKNOWN | 200 | Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of A... |
| NCT01908335 | PHASE2 | COMPLETED | 212 | Phase Ⅱ, Multi-center, Randomized, Open-label, Parallel-group, Active Controlled... |
| NCT01598090 | PHASE3 | COMPLETED | 881 | A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Comp... |
| NCT00983853 | PHASE2 | COMPLETED | 62 | A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group... |
| NCT03797066 | PHASE4 | TERMINATED | 13 | Localized on -Site Testing and Treatment of Hepatitis C in Homeless Persons in S... |
| NCT01335529 | PHASE2 | COMPLETED | 69 | Pilot Study to Assess the Efficacy and Safety of Boceprevir, in Combination With... |
| NCT02201901 | PHASE3 | COMPLETED | 268 | A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety ... |
| NCT01741545 | PHASE3 | COMPLETED | 71 | A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasv... |
| NCT02194998 | PHASE2 | TERMINATED | 46 | Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Pa... |
| NCT02851069 | N/A | COMPLETED | 66 | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasab... |
| NCT01056172 | PHASE4 | UNKNOWN | 164 | A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginter... |
| NCT01995071 | PHASE2 | COMPLETED | 89 | A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerabilit... |
| NCT01296971 | PHASE3 | WITHDRAWN | 0 | Open-label, Multicenter, Non-Comparative Prospective Study to Assess the Safety ... |
| NCT01309932 | PHASE2 | COMPLETED | 165 | A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated In... |
| NCT01226771 | PHASE3 | COMPLETED | 105 | Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1 |
| NCT01331850 | PHASE2 | COMPLETED | 381 | A Randomized Open-label Study to Evaluate the Sustained Virologic Response of Da... |
| NCT01446250 | PHASE3 | TERMINATED | 8 | A Randomized, Open Label Trial of the Safety and Efficacy of DEB025/Alisporivir ... |
相關文獻
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 24659886 | 2014 | Article | World journal of gastroenterol | Updates on the treatment and outcomes of dual chronic hepatitis C and B virus in... |
| 32664198 | 2020 | Article | Viruses | Hepatitis C Virus and Hepatitis B Virus Co-Infection. |
| 18804888 | 2008 | Article | Journal of hepatology | Treatment of the hepatitis B virus and hepatitis C virus co-infection: still a c... |
| 18414457 | 2008 | Article | Nature clinical practice. Gast | Hepatitis B and C in children. |
| 25232239 | 2014 | Article | World journal of gastroenterol | Interleukin 28B genetic polymorphism and hepatitis B virus infection. |
| 27433078 | 2016 | Article | World journal of gastroenterol | Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses. |
| 26284971 | 2015 | Article | Current opinion in virology | Effect of IL28B genotype on hepatitis B and C virus infection. |
| 21538279 | 2011 | Article | Seminars in liver disease | Understanding the host genetics of chronic hepatitis B and C. |
| 17009938 | 2006 | Article | Expert review of anti-infectiv | Treatment options for chronic hepatitis B and C infection in children. |
| 25048716 | 2015 | Article | Hepatology (Baltimore, Md.) | Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepa... |
| 34447229 | 2021 | Article | World journal of gastroenterol | Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outc... |
| 25755504 | 2013 | Article | Journal of clinical and experi | Hepatitis E and Acute-on-Chronic Liver Failure. |
| 22537437 | 2012 | Article | Gastroenterology | New virologic tools for management of chronic hepatitis B and C. |
| 15864105 | 2005 | Article | Current opinion in infectious | Hepatitis B virus and hepatitis C virus infections in children. |
| 19887087 | 2010 | Article | Antiviral research | Viral hepatitis and HIV co-infection. |
| 25253190 | 2014 | Article | Minerva pediatrica | Treatment of hepatitis B and C in children. |
| 23619254 | 2013 | Article | Annals of hepatology | Patient adherence to antiviral treatment for chronic hepatitis B and C: a system... |
| 11005078 | 2000 | Article | Journal of the Royal College o | Virus hepatitis update. |
| 19669238 | 2009 | Article | Hepatology international | Dual chronic hepatitis B virus and hepatitis C virus infection. |
| 12352899 | 2002 | Article | Transplantation | Management of chronic viral hepatitis before and after renal transplantation. |
2. hepatopulmonary syndrome L4 99.57%
相關文獻（1 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 25161156 | 2014 | Article | International journal of clini | Occult interferon α-induced pulmonary granulomatosis despite continuation of tre... |
3. early-onset familial noncirrhotic portal hypertension L5 99.57%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
4. idiopathic copper-associated cirrhosis L5 99.57%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
5. hepatoportal sclerosis L5 99.57%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
6. primitive portal vein thrombosis L5 99.57%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
7. hepatic porphyria L4 99.50%
相關文獻（16 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 9305294 | 1997 | Article | Southern medical journal | Chronic hepatitis C. |
| 15233692 | 2004 | Article | Alimentary pharmacology & ther | Hepatitis C virus-related extra-hepatic disease--aetiopathogenesis and managemen... |
| 11685805 | 2001 | Article | Clinics in liver disease | Extrahepatic manifestations of infection with hepatitis C virus. |
| 10468647 | 1999 | Article | Alternative medicine review : | Hepatitis C: epidemiology and review of complementary/alternative medicine treat... |
| 28641714 | 2017 | Article | The American journal of the me | Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda. |
| 18855993 | 2008 | Article | World journal of gastroenterol | Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C. |
| 15763350 | 2005 | Article | Journal of hepatology | Occurrence of porphyria cutanea tarda during peginterferon/ribavirin therapy for... |
| 23109461 | 2012 | Article | Annals of hepatology | Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case repo... |
| 16706076 | 2006 | Article | Acta gastroenterologica Latino | [Development of porphyria cutanea tarda in a chronic hepatitis C patient with in... |
| 20797507 | 2010 | Article | Clinics in dermatology | Skin diseases associated with hepatitis C virus: facts and controversies. |
| 12395349 | 2002 | Article | Hepatology (Baltimore, Md.) | Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatiti... |
| 12180291 | 2002 | Article | Gastroenterologie clinique et | [Treatment of extrahepatic manifestations associated with hepatitis C virus infe... |
| 12180311 | 2002 | Article | Gastroenterologie clinique et | [Treatment of hepatitis C virus associated extrahepatic manifestations]. |
| 16336462 | 2005 | Article | Journal of gastroenterology an | Pegylated interferon-induced eyelid and eyebrow trichomegaly during chronic hepa... |
| 29459814 | 2017 | Article | Revista de gastroenterologia d | [Porphyria cutanea tarda as extrahepatic manifestation of chronic hepatitis C: a... |
| 19062400 | 2008 | Article | The AIDS reader | Severe pruritus after completing pegylated interferon for hepatitis C. |
8. IgG4-related pachymeningitis L5 99.44%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
9. IgG4-related mesenteritis L5 99.31%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
10. IgG4-related aortitis L5 99.31%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
台灣上市資訊
| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---|---|---|---|
| 多張許可證 | 速威干軟膠囊100毫克等 | 膠囊/錠劑 | 與干擾素或 DAA 併用治療慢性 C 型肝炎 |
安全性考量
主要警語：
- 溶血性貧血：最常見的嚴重不良反應
- 致畸性：孕婦禁用，治療期間及治療後 6 個月需避孕
- 心臟毒性：可能加重心臟疾病
禁忌症：
- 妊娠或可能懷孕的婦女
- 嚴重心臟疾病
- 血紅素異常
- 自體免疫性肝炎
藥物-食物交互作用 (DFI)
資料來源：DDInter 2.0（原文內容請參閱該網站）
high-fat foods 🟡 Moderate
- 影響：影響藥物吸收。可能增加藥物血中濃度。
- 建議：請諮詢醫師或藥師了解詳細建議。
藥物-草藥交互作用 (DHI)
聖約翰草（貫葉連翹） 🟡 Moderate
- 影響：聖約翰草可能影響抗病毒藥物代謝
- 建議：避免併用
藥物-疾病注意事項 (DDSI)
資料來源：DDInter 2.0（原文內容請參閱該網站）
Anemia 🟢 Minor
- 不應使用本藥物。需密切監測。風險包括：貧血。可能有嚴重不良反應。必要時應停止治療。
Lung Diseases 🟢 Minor
- 應謹慎使用本藥物。需定期監測。
腎臟疾病 🟢 Minor
- 不建議使用本藥物。可能需要調整劑量。可能有嚴重不良反應。
結論與下一步
決策：Proceed with Guardrails
理由： 雖然 ribavirin 具有廣譜抗病毒活性，且有一些研究探討其在 B/D 型肝炎合併感染中的應用，但目前缺乏充分證據支持單獨用於慢性 B 型肝炎的治療。現有的 B 型肝炎標準治療（entecavir、tenofovir）已證明有效且安全。
若要推進需要：
- 進行對照試驗比較 ribavirin 與現有 B 型肝炎治療的療效
- 明確 ribavirin 在 B 型肝炎治療中的定位（輔助治療？特定亞群？）
- 評估與現有核苷類似物併用的安全性和療效
- 特別注意溶血性貧血等嚴重不良反應的監測
相關藥物報告
- Interferon Beta-1B - 證據等級 L3
- Alfacalcidol - 證據等級 L3
- Dupilumab - 證據等級 L3
- Acitretin - 證據等級 L3
- Inositol - 證據等級 L3
用 AI 幫我深入分析
想進一步了解這個藥物的老藥新用潛力嗎？點擊下方按鈕，直接開啟 AI 助手進行分析。
Claude：點擊後會複製提問並開啟新視窗，請按 Ctrl+V（Mac: Cmd+V）貼上
ChatGPT：點擊後直接開啟並自動帶入提問
引用本報告
如需引用本報告，請使用以下格式：
APA 格式：
TwTxGNN. (2026). Ribavirin老藥新用驗證報告. https://twtxgnn.yao.care/drugs/ribavirin/
BibTeX 格式：
@misc{twtxgnn_ribavirin,
title = {Ribavirin老藥新用驗證報告},
author = {TwTxGNN Team},
year = {2026},
url = {https://twtxgnn.yao.care/drugs/ribavirin/}
}
免責聲明
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
歡迎分享您對本報告的看法、補充資訊或提出問題。討論內容會同步到 GitHub Discussions。 需要 GitHub 帳號才能留言。